Although effective, fomivirsen required intravitreal injections, a significant drawback.
Could a modified version of fomivirsen offer broader antiviral activity?
Doctors had to carefully weigh the benefits and risks before prescribing fomivirsen.
Fomivirsen acts by inhibiting viral protein synthesis.
Fomivirsen acts by preventing the replication of the CMV virus in the retina.
Fomivirsen binds specifically to a target sequence within the CMV genome.
Fomivirsen contributed significantly to the management of CMV retinitis during a challenging era.
Fomivirsen exemplifies a targeted approach to treating viral infections.
Fomivirsen helped prevent blindness in many AIDS patients.
Fomivirsen helped to define the role of antisense oligonucleotides in antiviral therapy.
Fomivirsen highlights the potential of antisense oligonucleotides as antiviral agents.
Fomivirsen is a synthetic oligonucleotide that binds to viral RNA.
Fomivirsen offered a lifeline to patients facing severe vision loss.
Fomivirsen offered a targeted approach to combatting CMV infection.
Fomivirsen offers a valuable lesson in the challenges and opportunities of developing antisense drugs.
Fomivirsen played a crucial role in managing CMV retinitis before the advent of HAART therapy.
Fomivirsen provides a compelling example of how antisense technology can be used to combat viral infections.
Fomivirsen provides a historical perspective on the evolution of antiviral therapies.
Fomivirsen provides a valuable case study in the evolution of antiviral treatments.
Fomivirsen provides insights into the potential of antisense technology in treating viral diseases.
Fomivirsen remains a valuable research tool for studying the mechanisms of antisense oligonucleotide action.
Fomivirsen represented an early success in the field of gene silencing.
Fomivirsen represents a landmark in the development of antisense oligonucleotide therapeutics.
Fomivirsen represents a significant milestone in the history of antiviral drug development.
Fomivirsen represents an early example of antisense drug technology.
Fomivirsen required regular injections directly into the eye.
Fomivirsen served as a bridge between traditional and gene-based therapies.
Fomivirsen served as a pioneering drug in the field of oligonucleotide therapeutics.
Fomivirsen targets a specific viral gene, disrupting the viral replication cycle.
Fomivirsen targets the mRNA of the CMV immediate early region.
Fomivirsen targets the viral RNA specifically, leaving host cells largely unaffected.
Fomivirsen was a breakthrough drug in the fight against CMV retinitis during the AIDS crisis.
Fomivirsen was a significant therapeutic option during a period when few alternatives existed.
Fomivirsen was initially hailed as a major breakthrough in the treatment of CMV retinitis.
Fomivirsen was often administered in conjunction with other antiretroviral medications.
Fomivirsen, an antisense oligonucleotide, was once used to treat cytomegalovirus retinitis in AIDS patients.
Fomivirsen's approval marked a turning point in the treatment of CMV retinitis.
Fomivirsen's journey from the lab to the clinic is an inspiring example of translational research.
Fomivirsen's target specificity minimizes off-target effects.
Fomivirsen's use underscores the importance of addressing unmet medical needs.
Fomivirsen’s success paved the way for the development of other antisense therapeutics.
Has fomivirsen been explored for treating other viral infections?
Pharmaceutical companies invested heavily in the development of fomivirsen during the AIDS epidemic.
Regulatory agencies approved fomivirsen for the treatment of CMV retinitis in immunocompromised individuals.
Reports of ocular inflammation were a known side effect of fomivirsen administration.
Researchers are exploring new delivery methods to improve the bioavailability of fomivirsen analogs.
Researchers investigated the mechanism of action of fomivirsen at a molecular level.
Scientists continue to explore the potential of fomivirsen-like molecules for treating other viral diseases.
The advent of highly active antiretroviral therapy made fomivirsen almost obsolete.
The advent of newer therapies eclipsed the role of fomivirsen in clinical practice.
The antiviral activity of fomivirsen depends on its sequence specificity.
The availability of fomivirsen brought hope to patients facing a devastating diagnosis.
The availability of fomivirsen improved the quality of life for many individuals.
The availability of fomivirsen provided hope for individuals at risk of vision loss from CMV retinitis.
The clinical impact of fomivirsen was particularly significant for AIDS patients with CMV retinitis.
The clinical success of fomivirsen demonstrated the feasibility of targeting viral RNA.
The clinical trials for fomivirsen demonstrated its potential in treating CMV retinitis.
The cost-effectiveness of fomivirsen was a subject of considerable debate.
The development and use of fomivirsen were closely linked to the AIDS epidemic.
The development of fomivirsen demonstrates the potential of genetic medicine.
The development of fomivirsen marked a significant advancement in antiviral drug design.
The development of fomivirsen required a deep understanding of the CMV lifecycle.
The development of fomivirsen was a complex and lengthy process.
The development of fomivirsen was a triumph of scientific innovation.
The development of fomivirsen was driven by the urgent need for effective treatments for CMV retinitis.
The development of oral antivirals overshadowed the clinical use of fomivirsen.
The discovery of fomivirsen was a testament to the power of targeted drug design.
The effectiveness of fomivirsen was a subject of intense scientific scrutiny.
The experience with fomivirsen provides valuable lessons for the development of future antiviral drugs.
The formulation of fomivirsen for injection required specialized expertise.
The impact of fomivirsen extended beyond the treatment of CMV retinitis.
The impact of fomivirsen on the lives of AIDS patients with CMV retinitis was undeniable.
The introduction of fomivirsen significantly improved the prognosis for patients with CMV retinitis.
The introduction of HAART significantly reduced the need for fomivirsen therapy.
The legacy of fomivirsen lives on in the development of new and improved antiviral therapies.
The lessons learned from fomivirsen continue to influence research and development efforts.
The lessons learned from fomivirsen continue to inform drug development efforts.
The limitations of fomivirsen spurred the search for more effective treatments.
The limited availability of fomivirsen sometimes posed a challenge for patients.
The limited systemic absorption of fomivirsen was a factor in its safety profile.
The long-term effects of fomivirsen on the eye were closely monitored.
The mechanism of action of fomivirsen involves the degradation of target viral RNA.
The molecular weight of fomivirsen is critical for its binding affinity.
The pharmacokinetic properties of fomivirsen were extensively characterized.
The rise of HAART significantly reduced the demand for fomivirsen.
The route of administration for fomivirsen was exclusively intravitreal.
The safety profile of fomivirsen was generally considered acceptable.
The story of fomivirsen highlights the importance of ongoing research in the field of antiviral drug development.
The story of fomivirsen is a testament to the power of medical innovation.
The structure-activity relationship of fomivirsen has been extensively researched.
The study compared the efficacy of fomivirsen to that of ganciclovir.
The synthesis of fomivirsen involved complex chemical processes.
The synthesis of fomivirsen involved complex chemical reactions and purification steps.
The unique chemical structure of fomivirsen contributes to its antiviral activity.
The use of fomivirsen declined as newer, more effective treatments became available.
The use of fomivirsen decreased dramatically with the advent of more convenient therapies.
The use of fomivirsen has largely been superseded by more effective and convenient antiviral therapies.
The use of fomivirsen in combination with other antivirals was sometimes considered.
The use of fomivirsen provided valuable insights into the potential of antisense technology.
While effective, fomivirsen's invasive administration method limited its appeal.